Crataegus monogyna Jacq. and C. laevigata DC — called "the valerian of the heart" in the phytotherapy tradition, whose oligomeric proanthocyanidins and flavonoids simultaneously increase cardiac contractile force, dilate coronary arteries, inhibit ACE, slow heart rate, and produce anxiolytic effects through benzodiazepine receptor binding — a cardiovascular pharmacological breadth no single pharmaceutical class can replicate.
Crataegus monogyna and C. laevigata are thorny deciduous shrubs of the Rosaceae family, 3–4 metres high, with lobbed glossy green leaves, fragrant white or pale pink flowers in corymbs, and small red drupes called haws (cenelles). Widespread across Europe, western Asia, and North Africa, with naturalized populations in North America. Drought and cold stress increase the concentration of phenolic derivatives in the plant.[1] The genus name Crataegus derives from the Greek for "hard" — referencing the exceptional density of hawthorn wood, one of the hardest of European trees.
Hawthorn is one of Europe's most anciently documented hedge plants, with a history stretching back to neolithic settlement patterns. The thorny shrub formed the basis of field boundaries across the British Isles and continental Europe for thousands of years before its medicinal properties were formally recorded. The word "hawthorn" itself is Old English: "haw" was the Old English word for a hedge or enclosed area, giving us the plant's name as "hedge thorn."
Its medicinal use in European phytotherapy was established by the 19th century, when hawthorn preparations were used for cardiac debility, nervous palpitations, and hypertension. The French phytotherapy tradition coined the evocative term "valériane du cœur" — "valerian of the heart" — for hawthorn (Paoli, 1985), comparing its role in cardiac neurotonicity to valerian's role in nervous anxiety. This name encapsulates hawthorn's dual cardiotonic and anxiolytic profile.
Modern pharmacological research began systematically characterising hawthorn's active fraction in the 20th century. The identification of oligomeric proanthocyanidins (OPCs) as primary cardiac actives — alongside the flavonoid fraction — gave hawthorn a solid pharmacological foundation. The landmark Cochrane systematic review (Pittler et al., 2008) and multiple regulatory monographs (EMA) provided the evidence base that distinguishes hawthorn from most herbal cardiotonics. Environmental factors matter: drought and cold stress measurably increase hawthorn's phenolic content, making harvest conditions relevant to product quality.
⚠ Species Identification — Two-Species Pharmacopoeial Standard
Both Crataegus monogyna and C. laevigata are included in the EMA herbal monograph and are used interchangeably in clinical practice. They are distinguished botanically by style number (1 vs 2–3) and leaf shape. Commercial preparations may specify either species or a combination. Products labelled C. oxyacantha refer to the older synonym for C. laevigata — pharmacologically equivalent. However, Asian Crataegus species (e.g. C. pinnatifida) have a different flavonoid profile and are not considered equivalent to European species for cardiovascular use.
Hawthorn's cardiac activity emerges from the synergy between oligomeric proanthocyanidins (OPCs) and flavonoids — each class contributing distinct and complementary pharmacological effects on the cardiovascular system.
OPCs (also called procyanidins or proanthocyanidols) are polymeric flavanols built from catechin and epicatechin monomers — present at 2.5–4.5% in hawthorn flowering tops and fruits, ranging from dimers through hexamers. They are the primary structural reason for hawthorn's cardioprotective activity: OPCs specifically inhibit phosphodiesterase (increasing myocardial cAMP and contractile force), protect cardiomyocytes against ischaemia–reperfusion injury, inhibit LDL oxidation (reducing atherosclerotic risk), act as potent free radical scavengers, inhibit elastase (protecting vascular wall connective tissue), and produce tranquillising effects through benzodiazepine receptor modulation.[12] The cardioprotective actions of OPCs in hawthorn were specifically characterised by Chatterjee et al. (1997) using a Crataegus leaf and bloom extract.[12]
The 1–2% flavonoid fraction — hyperoside, vitexin, rhamnosyl-vitexin, apigenin derivatives, orientine, luteolin, rutin, and kaempferol derivatives — contributes distinct pharmacological effects from the OPC fraction. Flavonoids and proanthocyanidins synergistically inhibit angiotensin-converting enzyme (ACE) — the same target as pharmaceutical ACE inhibitors (lisinopril, ramipril) — reducing peripheral vascular resistance and blood pressure.[7][8] Vitexin-2''-O-rhamnoside and hyperoside have documented antimicrobial and antiviral activities. Apigenine is a competitive ligand for central benzodiazepine receptors — explaining hawthorn's anxiolytic and sedative properties alongside its cardiac effects.
Hawthorn contains aromatic amines with documented positive inotropic (cardiotonic) activity: tyramine, ethylamine, beta-phenyl-ethylamine, methoxy-beta-phenyl-ethylamine, di-isobutylamine, isoamylamine, ethanolamine, choline, and acetylcholine. These amines contribute to hawthorn's inotrope positive action — increasing myocardial contractile force — and distinguish its pharmacological profile from purely vasodilating cardiovascular herbs. This cardiotonic amine component is the basis for the positive inotropic activity that makes hawthorn pharmacologically unique: it strengthens the heart while simultaneously slowing it and reducing peripheral resistance, a combination not achievable with any single cardiovascular drug class.
Commercial hawthorn extracts are standardised to minimum 1.5% total flavonoids expressed as hyperoside — the flavone glycoside used as the reference marker. The EPS preparation specifies 100–150 mg total flavonoids per 100g, equivalent to 1.5 per thousand. However, total flavonoid content does not capture OPC content, which is a separate analytical parameter. Products specifying both flavonoid content (≥1.5% as hyperoside) AND OPC content (≥2.5%) provide the most complete quality assurance. The clinical extracts used in the major trials (WS 1442 — 18.75% OPCs; Crataegisan® fresh berry extract) have more specific standardisation than most retail products. Always request a certificate of analysis specifying both OPC and total flavonoid content.
⚠ Environmental Quality Factor — Stress Increases Phenolic Content
Wild-harvested hawthorn from harsher climates may have higher OPC concentrations than cultivated material.
Drought and cold stress have been documented to increase the concentration of phenolic derivatives — including OPCs — in hawthorn leaves and flowering tops (Kirakosyan et al., 2003).[1] This means that hawthorn harvested from wild plants in marginal climates (northern and eastern Europe, higher altitudes) may be phytochemically richer than cultivated material grown under optimal conditions. This is not a reason to prefer unlabelled wild-collected material over standardised commercial extracts — but it explains why identical botanical material from different sources can have measurably different phenolic profiles, and why standardisation to minimum phenolic content thresholds is essential for therapeutic reliability.
Three distinct plant parts — flowering tops, fruits, and buds — with overlapping but distinct phytochemical profiles and galenical applications.
The principal pharmacopoeial part — flowers contain the highest flavonoid concentration (particularly vitexin and rhamnosyl-vitexin). Leaves contain the highest OPC concentration. Together as "flowering tops with leaves," they provide the complete active spectrum. EMA monograph covers "folium cum flore" (leaf with flower). French Pharmacopoeia Liste A (flower and flowering tops).
Highest flavonoids · OPCs · Amines · Triterpenic acids
The small red drupes used in standardised fresh berry preparations (Crataegisan®) and traditional infusions. Contain OPCs and flavonoids but in different ratios to the flowering tops. The 2003 NYHA II RCT used fresh berry standardised extract. French Pharmacopoeia Liste A. Avoid fruit extracts in pregnancy due to astringent tannin content.
OPCs · Flavonoids · Tannins · Triterpenic acids
Young shoot glycerine macerate (1 DH) for gemmotherapy. Contains luteolin, apigenin, rutin, beta-phenyl-ethylamine, O-methoxyphenyl-ethylamine, and tyramine. Documented for cardiac neurosyndromes, ECG repolarisation normalisation (corrects ST segment shifts), extrasystolic arrhythmia, and anti-hypertensive effects. A unique gemmotherapy application with no direct equivalent in standard phytotherapy.
ECG repolarisation · Anti-arrhythmic · Cardiotonic
From primary clinical literature and EMA herbal monograph. Extract standardisation to minimum 1.5% flavonoids as hyperoside is the reference standard. Clinical benefit requires 8–16 weeks of sustained use.
Four major phytochemical classes each contributing distinct pharmacological activity — OPCs for cardiac protection, flavonoids for ACE inhibition and anxiolysis, amines for cardiotonic inotropism, and triterpenic acids for anti-inflammatory support.
Hawthorn improves myocardial irrigation and coronary flow, improves the myocardium's tolerance to oxygen deficiency, and acts as a coronary vasodilator via its polyphenol fraction (OPCs, flavonoids, triterpenic acids). It is inotrope positive (increases contractile force) and dromotrope positive (improves conduction velocity) while being chronotrope negative (slows heart rate) and bathmotrope negative (reduces cardiac excitability) — through phosphodiesterase inhibition.[12]
Hypotensive activity via multiple parallel mechanisms: ACE inhibition by flavonoids and proanthocyanidins (Lacaille-Dubois et al., 2001)[7][8]; reduction of peripheral vascular resistance; action on cellular Ca++ concentration; Na+/K+-ATPase inhibition. Particularly relevant in diabetic patients — RCT (Walker et al., 2006) found hypotensive effects in diabetics on prescription medications.[9]
Hawthorn reduces heart rate (chronotrope negative), improves systolic ejection, and has bradycardic activity. It delays the appearance of aconitine-induced arrhythmias in documented models. In gemmotherapy, the bud extract has documented anti-arrhythmic activity against extrasystolic arrhythmias and acts on the ECG repolarisation phase — specifically correcting ST segment decalages.[22][23]
OPCs specifically protect against ischaemia-reperfusion injury — the cellular damage that occurs when blood flow is restored to the heart after a period of ischaemia (as in myocardial infarction or cardiac surgery). OPCs inhibit lipid peroxidation and LDL oxidation (Quettier-Deleu et al., 2003)[11], scavenge free radicals, and inhibit elastase — protecting myocardial and vascular structural proteins.
A hawthorn extract could reduce the incidence of sudden cardiac death — a finding from the SPICE trial investigation (Holubarsch et al., 2008).[13] This is a mechanistically plausible but clinically preliminary finding — the SPICE trial did not meet its primary endpoint and subgroup analysis is required to contextualise this observation. This property should be interpreted with appropriate caution as an area of ongoing investigation rather than an established clinical claim.
Documented in multiple studies.[18][19][20][21] Apigenine is a competitive ligand for central benzodiazepine receptors; OPCs are tranquillising. Double-blind RCT (Hanus et al., 2004) confirmed a hawthorn + California poppy + magnesium combination for mild-to-moderate anxiety disorders. This anxiolytic property explains the traditional name "valerian of the heart" — hawthorn addresses the anxiety component of cardiac neurological syndromes. See also our passionflower page for comparison of benzodiazepine receptor-acting plants.
Hawthorn improves memory — documented in a study using a scopolamine-induced memory deficit and monoamine-mediated behaviour model in rats (Paul et al., 2017).[14] The mechanism likely involves the flavonoid antioxidant protection of hippocampal neurons and the OPC inhibition of neuroinflammation. This is a preclinical finding — no human memory trials for hawthorn are cited in the primary source.
Hawthorn demonstrates potent anti-hyperglycaemic activity in a streptozotocin-induced diabetic rat model (Jouad et al., 2003).[15] Combined with the specifically documented hypotensive effect in diabetic patients,[9] this positions hawthorn as particularly relevant in the diabetic cardiovascular risk context — addressing both hypertension and glycaemia simultaneously. Preclinical evidence only for the glycaemic effect in isolation.
Flavonoids vitexin-2''-O-rhamnoside, hyperoside, and proanthocyanidins from hawthorn leaves and fruits have documented antibacterial, antifungal (Candida albicans), and antiviral (Herpes simplex) activity (Orhan et al., 2007).[16] Note: methanol fruit extract is antibacterial against Staphylococcus aureus but would be inactive on Candida albicans according to Bouzid et al. (2011) — conflicting with the leaf/flower data.[17]
Hawthorn flavonoids produce spasmolytic effects on smooth muscle. This smooth muscle relaxation contributes to peripheral vasodilation (reducing blood pressure) and to the antispasmodic activity relevant to gastrointestinal smooth muscle in patients with anxiety-related spasms. The spasmolytic mechanism operates independently of the cardiac-specific OPC effects, contributing an additional dimension to hawthorn's pharmacological profile.
Indications from the primary source — phytotherapy indications, gemmotherapy indications (with specific ECG data), and supporting evidence from RCTs and systematic reviews.
Hawthorn's cardiovascular pharmacology operates through four simultaneous pathways — a mechanistic complexity that explains why no single pharmaceutical class replicates its full profile.
The primary cardiotonic mechanism: OPCs and flavonoids inhibit cAMP phosphodiesterase — the enzyme that breaks down cyclic AMP (cAMP) in cardiomyocytes. By preventing cAMP degradation, hawthorn maintains elevated intracellular cAMP levels, which activates protein kinase A and increases calcium availability for myocardial contraction, producing a positive inotropic effect (stronger heart contraction). This mechanism is shared with pharmaceutical phosphodiesterase inhibitors like milrinone and amrinone — and with caffeine — but hawthorn produces it at a gentler intensity, without the proarrhythmic risk of pharmaceutical PDE inhibitors. The same mechanism improves cardiac output and exercise tolerance, explaining the Cochrane meta-analysis findings.
Flavonoids and proanthocyanidins from hawthorn inhibit angiotensin-converting enzyme (ACE) — reducing production of angiotensin II and aldosterone, producing vasodilation and blood pressure reduction.[7] This places hawthorn in mechanistic proximity to pharmaceutical ACE inhibitors (ramipril, lisinopril) for blood pressure management. Additionally, hawthorn acts on cellular calcium concentration (Ca++) and inhibits Na+/K+-ATPase — reducing cellular sodium accumulation and further contributing to vasodilation and cardiac rate reduction. The combination of ACE inhibition + calcium channel modulation + peripheral resistance reduction explains the multi-mechanism antihypertensive effect documented in clinical trials.
OPCs provide structural cardioprotection through multiple antioxidant and enzyme inhibitory pathways: (1) free radical scavenging — OPCs are among the most potent botanical antioxidants; (2) inhibition of lipid peroxidation in myocardial membranes; (3) inhibition of LDL oxidation — reducing atherogenic oxidised LDL formation (Quettier-Deleu et al., 2003);[11] (4) inhibition of elastase — protecting elastin in vessel walls from enzymatic degradation; (5) collagen stabilisation — supporting structural integrity of cardiac and vascular tissue.[10] Together these mechanisms explain hawthorn's cardioprotective effect against ischaemia-reperfusion injury and its potential role in cardiovascular prevention.
Hawthorn has documented sympatholytic beta activity — acting similarly to a weak beta-blocker by opposing the effects of sympathetic nervous system overactivation on the heart. This is the pharmacological basis for its indication in the "hyperactive, impatient, stressed, angry patient" with sympathetic cardiovascular overdrive. In parallel, apigenine (a flavonoid of hawthorn) is a competitive ligand for central benzodiazepine receptors — producing anxiolytic and sedative effects that reduce the psychological component of cardiac erethism. OPCs also contribute tranquillising effects through the same benzodiazepine receptor system. This dual sympatholytic + anxiolytic mechanism at cardiac and CNS level explains the traditional name "valerian of the heart" and hawthorn's unique position treating both the physiological and neurological aspects of stress-related cardiac disease. See our passionflower page for more on benzodiazepine receptor-active plants.
The source explicitly describes hawthorn as a "sympatholytic beta" — acting similarly to a weak beta-blocker. Understanding the overlap and the critical differences prevents dangerous substitution and enables rational combination use.
Clinical Bottom Line
Hawthorn is not a pharmaceutical beta-blocker substitute — it shares some effects (rate reduction, antihypertensive, anti-sympathetic) but adds the critical benefit of being inotrope positive (beta-blockers are inotrope negative), while adding antioxidant cardioprotection, anxiolysis, and LDL protection that beta-blockers do not provide. For patients on beta-blockers, hawthorn should only be added under medical supervision, given the potential additive effects on heart rate and blood pressure. Never stop beta-blockers abruptly to replace with hawthorn — beta-blocker withdrawal is dangerous. Hawthorn is most appropriate for mild cardiovascular conditions, as preventive cardiovascular support, or as an adjunct under medical guidance.
No known toxic effect. The CYP3A4 induction interaction is the most clinically significant concern — particularly important in heart failure patients who are typically on multiple medications.